Join the club for FREE to access the whole archive and other member benefits.


Company that target cancer by developing senescence inducing and senolytic (senescent cell killing) compounds.

Healthy cells use the preprogrammed mechanism of senescence to prevent becoming malignant. In contrast to normal cells, one of the hallmarks of cancer cells is the capability to escape senescence, thus acquiring a limitless replicative potential that is the prelude to invasion, metastasis and additional features of malignancy. At Oncosence we screen and develop compounds that selectively enhance senescence in cancer cells. However, recent advances suggest that if senescent tumour cells are not cleared from the tumors, they may promote tumour progression and metastasis we screen and develop senolytic agents that specifically target senescent cells. This two punch approach stops cancer growth by driving cancer cells in to senescent state and consecutively clears cancer cells in senescent state.

Visit website:

Oncosence News

LMC provides background and success outlook on 14 leading senolytic companies

Longevity Marketcap - 15-Dec-2020

Comprehensive review of companies' clinical and financial state of play


Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology - 12-Nov-2020

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...